Skip to main content
TipRanks
Go Ultimate75% OFF

Irhythm Technologies (0A7L) AI Stock Analysis

0 Followers
GB:0A7L

Irhythm Technologies

(LSE:0A7L)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue GrowthBroad-based revenue growth, led by Zio Monitor and supported by new-account volume, primary care, international markets, and innovative channels, indicates durable demand expansion. Continued double-digit growth would increase operating scale and strengthen iRhythm’s position across cardiac monitoring workflows.
Negative Factors
High LeverageDebt substantially exceeds the equity base, leaving iRhythm with limited balance-sheet flexibility relative to its operating scale. High leverage can constrain acquisitions, investment, and resilience during execution setbacks, while debt obligations may compete with funding for growth and product development.

Irhythm Technologies (0A7L) vs. iShares MSCI United Kingdom ETF (EWC)

-60%-40%-20%0%20%40%GB:0A7L-47.01%EWC+13.07%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$3.17B
Dividend Yield
―
Average Volume (3M)
122
Price to Earnings (P/E)
-80.5
Beta (1Y)
0.82
Revenue Growth
21.56%
EPS Growth
27.87%
Country
UK
Employees
2,400
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Irhythm Technologies Business Overview & Revenue Model

Company Description

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company...

Irhythm Technologies Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-24.92%|Next Earnings Date:Feb 25, 2027
Earnings Call SentimentPositive

The call was predominantly positive, supported by 14.9% revenue growth, record adjusted EBITDA profitability, improved adjusted net income, strong underlying cash generation, raised 2026 guidance, and the strategic expansion from VitalConnect. The main negative factors were flat Zio AT revenue, near-term customer onboarding delays, the postponement of the Zio MCT FDA filing to 2027, the GAAP loss and negative reported free cash flow caused by the litigation settlement, and ongoing regulatory and market-access work. Highlights significantly outweighed the lowlights, although management acknowledged near-term uncertainty in the MCT transition.

Positive Updates

Strong Third-Quarter Revenue Growth
Third-quarter revenue was $221.6 million, up 14.9% year-over-year despite cycling more than 30% growth in the third quarter of 2025. Performance was consistent with guidance, with the core Zio Monitor business outperforming expectations and benefiting from durable demand across primary care, innovative channels, international markets, strong volume growth, modest pricing gains, and continued strong collections.

Negative Updates

Zio AT Revenue Was Flat and Customer Onboarding Slowed
Zio AT revenue was roughly flat year-over-year in the third quarter, below expectations for growth generally in line with the overall business. Management said new-account onboarding slowed because customers delayed integrating Zio AT while waiting to access the combined VitalConnect portfolio. The company expects these dynamics to persist in the near term; fourth-quarter Zio AT revenue is expected to be down about 10% on a dollar basis, with volume flat year-over-year.

Company Guidance

Management raised full year 2026 revenue guidance to $890 million to $895 million, representing 19% to 20% year-over-year growth, assuming Zio Monitor year-over-year growth of mid-teens in Q4, approximately $16 million of VitalConnect revenue in Q4, and Zio AT sequentially flat to Q3; Zio AT is expected to be down about 10% on a dollar basis and flat year-over-year on a volume basis in Q4. Organic iRhythm gross margin is expected to remain generally consistent with third quarter levels, excluding the onetime benefit associated with tariff refunds, with total company gross margin above 70% in the fourth quarter, while full year adjusted EBITDA margin guidance was raised to 15.5% to 16%; excluding certain onetime items, free cash flow is expected to increase year-over-year in 2026, with positive free cash flow generation in the fourth quarter. For 2027, the organic iRhythm business is expected to track toward approximately $1 billion in revenue, with Zio Monitor growth in the mid-teens, Zio AT flat versus 2026, and VitalConnect growth slightly above organic iRhythm growth, or mid to high teens, relative to the $65 million run rate in 2026; the company expects gross margin above 70% and an adjusted EBITDA margin of at least 15%.

Irhythm Technologies Risk Analysis

Irhythm Technologies disclosed 126 risk factors in its most recent earnings report. Irhythm Technologies reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Increasing our financial leverage could affect our operations and profitability.Q3, 2026
2.Increasing our financial leverage could affect our operations and profitability.Q3, 2026
3.Failure to comply with covenants in the Credit Agreement could result in our inability to borrow additional funds and adversely impact our business.Q3, 2026

Irhythm Technologies Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0A7L against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MDTMDT81Outperform$128.70B24.6610.60%2.84%9.77%12.28%
GEHCGEHC79Outperform$37.03B17.2819.85%0.18%6.87%-2.26%
ABTABT67Neutral$179.90B38.519.11%2.43%10.00%-66.06%
PHGPHG67Neutral$28.53B26.578.44%3.38%――
BSXBSX64Neutral$62.31B18.1413.87%―8.88%25.77%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%20%GB:0A7LABTBSXPHGMDTGEHCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0A7L and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0A7LIrhythm Technologies97.00-82.66-46.01%
ABTAbbott Laboratories103.87-21.13-16.91%
BSXBoston Scientific42.99-53.89-55.63%
PHGKoninklijke Philips N.V.29.252.8610.84%
MDTMedtronic100.612.662.71%
GEHCGe Healthcare Technologies Inc.81.895.597.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.